PTCT · Ptc Therapeutics, Inc. · Financials
$62.62
-0.30 (-0.48%)
At close · Oct 21
View the 10-K filed Feb 19, 2026
Return incl. dividend (before tax)
Customer concentration
— top 4 customers 10% of revenue
4 customers — 10% of revenue (2025)
“During 2025, four of our distributors each accounted for over 10% of our net product sales.”
Market Cap
$5.25B
Shares
83.46M
Volume · Oct 21
935.73K
Avg daily vol (3M)
1.12M
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Revenue
$1.73B
+114.5%
FY2025
Net Income
$682.64M
+287.9%
FY2025
Gross Margin
96.05%
+0.8pp
FY2019
Operating Margin
50.09%
+87.6pp
FY2025
Diluted EPS
$7.78
+264.5%
FY2025
Operating Cash Flow
$711.2M
+760.4%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2026 (G) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $1.18B – $1.28B | $1.01B | $1.73BG | $806.78MG | $937.82MG | $698.8MG | $538.59MG | $380.77M | $306.98M | $264.73M | $194.39M | $82.71M | $36.77M | $25.25M | $34.7M | $33.95M | $105.41M | |
| — | — | — | — | — | — | — | — | $12.14M | $12.67M | $4.58M | $0 | $0 | — | — | — | — | |
| — | — | — | — | — | — | — | — | $294.85M | $252.06M | $189.82M | $82.71M | $36.77M | — | — | — | — | |
| — | — | — | — | — | — | — | — | 96.05% | 95.21% | 97.65% | 100% | 100% | — | — | — | — | |
| — | $433.31M | $455.25M | $534.48M | $666.56M | $651.5M | $540.68M | $477.64M | $257.45M | $171.98M | $117.46M | $117.63M | $121.82M | $79.84M | $54.88M | $46.14M | $58.68M | |
| — | — | — | — | — | — | — | — | — | — | $121.27M | $97.13M | $82.08M | $44.82M | $25.22M | $14.62M | $16.15M | |
| — | $347.73M | $347.14M | $300.91M | $332.54M | $326M | $285.77M | $245.16M | $202.54M | $153.55M | $121.27M | $97.13M | — | — | — | — | — | |
| — | $40.31M | $24.74M | $60.74M | $222.64M | $116.55M | $54.75M | $36.89M | $27.65M | $22.88M | $15.38M | $0 | $0 | — | — | — | — | |
| — | $55.3M | $38.82M | $75.66M | $236.59M | $128.84M | $64.13M | $43.49M | $32.18M | $26.09M | $17.68M | $3.29M | $2.88M | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | — | $0 | — | — | — | — | — | — | |
| — | $883.15M | $863.72M | $1.11B | $1.38B | $1.15B | $913.04M | $812.53M | $548.14M | $380.42M | $258.68M | $214.76M | $203.9M | $124.66M | $80.09M | $60.75M | $74.83M | |
| — | $125.6M | $866.94M | -$302.57M | -$439.5M | -$447.41M | -$374.44M | -$431.77M | -$241.16M | -$115.69M | -$64.29M | -$132.06M | -$167.13M | -$99.41M | -$45.4M | -$26.81M | $30.58M | |
| — | — | 50.09% | -37.5% | -46.86% | -64.03% | -69.52% | -113.39% | -78.56% | -43.7% | -33.07% | -159.67% | -454.58% | -393.79% | -130.85% | -78.97% | 29.01% | |
| — | $180.9M | $905.75M | -$226.91M | -$202.91M | -$318.57M | -$310.31M | -$388.28M | -$208.98M | -$89.6M | -$46.61M | -$128.77M | -$164.25M | — | — | — | — | |
| — | -$7.39M | -$18.09M | $6.54M | $10.13M | -$49.21M | -$57.88M | $85.19M | $13.72M | $129K | -$1.28M | -$1.21M | -$465K | -$213K | $38K | $1.78M | $461.36K | |
| — | -$67.07M | $696.62M | -$363.12M | -$696.11M | -$587.49M | -$518.34M | -$402.93M | -$239.93M | -$128.11M | -$77.67M | -$141.54M | -$169.96M | -$98.45M | -$51.57M | -$26.24M | $28.6M | |
| — | -$28.69M | $13.98M | $176K | -$69.51M | -$28.47M | $5.56M | $35.23M | $11.65M | -$29K | $1.34M | $569K | $485K | -$4.69M | — | — | -$2.31M | |
| — | -$38.38M | $682.64M | -$363.3M | -$626.6M | -$559.02M | -$523.9M | -$438.16M | -$251.58M | -$128.08M | -$79M | -$142.11M | -$170.45M | -$93.75M | -$51.57M | -$26.24M | $30.9M | |
| — | — | 39.44% | -45.03% | -66.81% | -80% | -97.27% | -115.07% | -81.95% | -48.38% | -40.64% | -171.83% | -463.6% | -371.37% | -148.65% | -77.28% | 29.32% | |
| — | -$38.38M | $682.64M | -$363.3M | -$626.6M | -$559.02M | -$523.9M | -$438.16M | -$251.58M | -$128.08M | — | — | -$170.45M | -$93.75M | -$66.43M | $731K | $26.07K | |
| — | -$39.72M | $719.03M | -$387.9M | -$632.69M | -$529.94M | -$487.23M | -$488.53M | -$263.62M | -$130.59M | -$73.55M | -$142.4M | -$170.91M | -$94.56M | -$51.5M | -$26.24M | $30.9M | |
| USD/shares | — | -$0.70 | $8.58 | -$4.73 | -$8.37 | -$7.79 | -$7.43 | -$6.64 | -$4.27 | -$2.75 | -$2.02 | — | — | -$2.97 | -$5.18 | $219.76 | $23.95 |
| USD/shares | — | -$0.54 | $7.78 | -$4.73 | -$8.37 | -$7.79 | -$7.43 | -$6.64 | -$4.27 | — | — | — | — | -$2.97 | -$5.18 | $42.50 | $4.55 |
| shares | — | — | 79.53M | 76.85M | 74.84M | 71.73M | 70.47M | 66.03M | 58.86M | 46.58M | 39.18M | 34.04M | 33.63M | 31.57M | 12.83M | 3328 | 1089 |
| shares | — | — | 88.31M | 76.85M | 74.84M | 71.73M | 70.47M | 66.03M | 58.86M | 46.58M | 39.18M | 34.04M | 33.63M | 31.57M | 12.83M | 17.21K | 5729 |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Current finance lease liabilities | 2026-06-30 | USD 6,000,000 | 10-Q filed 2026-07-30 |
| Current operating lease liabilities | 2026-06-30 | USD 11,965,000 | 10-Q filed 2026-07-30 |
| Current portion of long-term debt | 2026-06-30 | USD 55,451,000 | 10-Q filed 2026-07-30 |
| Noncurrent debt carrying amount | 2026-06-30 | USD 535,519,000 | 10-Q filed 2026-07-30 |
| Noncurrent operating lease liabilities | 2026-06-30 | USD 87,533,000 | 10-Q filed 2026-07-30 |
Instrument and agreement coverage is incomplete. Additional filings are awaiting review.
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
3.58×
Peer median 10.44×
EV/EBIT
28.77×
Peer median 26.96×
P/E (TTM)
—
Peer median 20.44×
Peer medians compare against the 181 similar-size Biotechnology companies (of 559 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Life Science Segment | $1,730,655,000 | $806,780,000 | $937,822,000 | $698,801,000 |
By Geography (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| United States | $252,185,000 | $207,215,000 | $255,087,000 | $381,862,000 | $297,005,000 | $186,396,000 | $116,676,000 | $93,694,000 |
| Non Us | $235,888,000 | $393,736,000 | $406,161,000 | $316,939,000 | $241,588,000 | $194,370,000 | $190,304,000 | $171,040,000 |
| All Other Countries Other Than Russia Brazil And United States | $168,412,000 | $197,472,000 | $238,510,000 | — | — | — | — | — |
| Russia | $100,445,000 | $105,377,000 | $85,974,000 | — | — | — | — | — |
| Brazil | $65,661,000 | $72,081,000 | $58,606,000 | — | — | — | — | — |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Collaboration and License Revenue | $998,357,000 | $304,000 | $100,030,000 | $50,052,000 | $55,046,000 | $42,579,000 | $15,674,000 | $1,729,000 |
| Product | $586,703,000 | $582,145,000 | $638,177,000 | $535,228,000 | $428,904,000 | $333,401,000 | $291,306,000 | $263,005,000 |
| Royalty | $244,224,000 | $203,864,000 | $168,856,000 | $113,521,000 | $54,643,000 | $4,786,000 | — | — |
| Translarna1 | $235,299,000 | $321,071,000 | $332,753,000 | — | — | — | — | — |
| Emflaza | $146,361,000 | $207,215,000 | $255,087,000 | — | — | — | — | — |
| Sephience | $111,153,000 | — | — | — | — | — | — | — |
| Upstaza and Kebilidi | $56,626,000 | $16,913,000 | $18,841,000 | — | — | — | — | — |
| Other Products | $37,264,000 | $36,946,000 | $31,496,000 | — | — | — | — | — |
| Translarna | -$98,629,000 | $18,806,000 | $23,072,000 | — | — | — | — | — |
| Manufacturing | — | $1,661,000 | $7,687,000 | — | — | — | — | — |
Key facts
CIK
1070081
CUSIP
69366J200
13F (30d)
37 filings
36 filers
Visit website
Investor relations